Glaukos (NYSE:GKOS) has entered into a licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.
Financial terms were not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.